BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37551111)

  • 1. Guanylate-binding proteins signature predicts favorable prognosis, immune-hot microenvironment, and immunotherapy response in hepatocellular carcinoma.
    Ning Y; Fang S; Fang J; Lin K; Nie H; Xiong P; Qiu P; Zhao Q; Wang H; Wang F
    Cancer Med; 2023 Aug; 12(16):17504-17521. PubMed ID: 37551111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
    Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
    Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
    Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
    Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
    Huang X; Qiu Z; Li L; Chen B; Huang P
    Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
    Liu R; Liu Y; Zhang F; Wei J; Wu L
    Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
    Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
    World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and clinical verification of immune-related genes in hepatocellular carcinoma to aid prognosis evaluation and immunotherapy.
    Qu J; Sun F; Hou Y; Qi H; Sun X; Xing L
    BMC Cancer; 2023 Jun; 23(1):549. PubMed ID: 37322434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction and validation of an IRF4 risk score to predict prognosis and response to immunotherapy in hepatocellular carcinoma.
    Yuan J; Liu Z; Wu Z; Yang J; Yang J
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109411. PubMed ID: 36461603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of angiogenesis-related subtypes of hepatocellular carcinoma and tumor microenvironment infiltration feature in hepatocellular carcinoma.
    Li W; Wu R; Zhang S; Zhao Y; Li L; Hu Z; Su Q; Mang Y; Zhang X; Dong Y; Zheng K; Ran J; Li L
    Clin Transl Oncol; 2023 Jul; 25(7):2099-2115. PubMed ID: 36708372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma.
    Zhang G; Zhang K; Zhao Y; Yang Q; Lv X
    BMC Cancer; 2022 Oct; 22(1):1103. PubMed ID: 36307751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
    Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
    Front Immunol; 2022; 13():990790. PubMed ID: 36248822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a Tumor Immunological Phenotype-Related Gene Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Hepatocellular Carcinoma.
    Tang Y; Guo C; Yang Z; Wang Y; Zhang Y; Wang D
    Front Immunol; 2022; 13():862527. PubMed ID: 35493471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor suppressor gene mutations correlate with prognosis and immunotherapy benefit in hepatocellular carcinoma.
    Liu Z; Liu L; Guo C; Yu S; Meng L; Zhou X; Han X
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108340. PubMed ID: 34789428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive study based on exosome-related immunosuppression genes and tumor microenvironment in hepatocellular carcinoma.
    Yang Z; Li X; Pan C; Li Y; Lin L; Jin Y; Zheng J; Yu Z
    BMC Cancer; 2022 Dec; 22(1):1344. PubMed ID: 36550445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the Prognosis Prediction Ability of a Necroptosis-Related Gene Signature and its Relationship With the Hepatocellular Carcinoma Immune Microenvironment Using Bioinformatics Analysis and Experimental Validation.
    Guan R; Mei J; Guo R
    Technol Cancer Res Treat; 2023; 22():15330338231182208. PubMed ID: 37335078
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma.
    Tan S; Guo X; Bei C; Zhang H; Li D; Zhu X; Tan H
    BMC Cancer; 2022 Aug; 22(1):905. PubMed ID: 35986302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response.
    Chen J; Chen X; Li T; Wang L; Lin G
    Int Immunopharmacol; 2022 Aug; 109():108866. PubMed ID: 35691273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NAPSB as a predictive marker for prognosis and therapy associated with an immuno-hot tumor microenvironment in hepatocellular carcinoma.
    Ning YM; Lin K; Liu XP; Ding Y; Jiang X; Zhang Z; Xuan YT; Dong L; Liu L; Wang F; Zhao Q; Wang HZ; Fang J
    BMC Gastroenterol; 2022 Aug; 22(1):392. PubMed ID: 35987606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment.
    Shi Y; Wang Y; Zhang W; Niu K; Mao X; Feng K; Zhang Y
    Front Endocrinol (Lausanne); 2023; 14():1153802. PubMed ID: 37469973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.